Clues to COVID origins via Wuhan wet market study 2017-2019 of severe fever with thrombocytopenia syndrome

By on .

By Daniel R. Lucey MD, MPH, FIDSA Retrospective testing for SARS-CoV-2 virus and antibody could be (or has been) done using blood and other samples highly likely to have been obtained from the 18 mammalian species (including masked palm civet, racoon dogs, and mink) reported in the Wuhan wet markets, May 2017-November 2019, as part […]

Not until June 2021 does China report Wuhan wet markets sold palm civets, racoon dogs and mink from 2017-2019: Where are the SARS-CoV-2 results?

By on .

By Daniel R. Lucey MD, MPH, FIDSA Last month a paper titled “Animal sales from Wuhan wet markets immediately prior to the COVID-19 pandemic” by Xiao et al., in Nature Scientific Reports listed 18 mammalian species sold May 2017 -November 2019 in Wuhan wet markets (Table 1).  These mammalian species included masked palm civets (Paguma […]

Why has no Gamma variant (P.1) been reported in Africa despite being found in 72 nations in the Americas, Asia, Europe and Australia? 

By on .

By Daniel R. Lucey MD, MPH, FIDSA Every week the World Health Organization posts an epidemiological update that includes global maps (below) and nation-by-nation listing in Annex 1 (below) for each of their four variants of concern: Alpha, Beta, Gamma, and Delta.  Multiple nations in Africa have reported Alpha, Beta, and Delta variants. In contrast, no […]

India declares Delta Plus (K417N) a Variant of Concern, and UK reports it is in 11 nations

By on .

By Daniel R. Lucey MD, MPH, FIDSA ​As the highly transmissible “Delta Variant” has spread to over 85 nations, on June 22 India also declared “Delta Plus” a Variant of Concern. The “plus” refers to the addition of a spike protein mutation, K417N, in the Delta Variant. This K417N mutation has been seen in other […]

What we’re reading: Four decades of HIV have wrought remarkable change, continuing loss, remaining challenges

By on .

The Science Speaks editorial staff (me) took some time off to attend to some long overdue family business in Michigan, thanks to an uptick in vaccine uptake and access there, a place now emerging from a recent discouraging surge of transmissions. Enjoying the benefits the remarkable accomplishments of science and public health have given us offered […]

WHO designates “Lambda” as global variant of interest

By on .

By Daniel R. Lucey MD, MPH, FIDSA In its weekly COVID-19 epidemiology update this week the World Health Organization stated that the “Lambda” was designated a variant of interest “based upon evidence of continued emergence and suspected phenotypic implications” (boldtype below was added). “Authorities in Peru reported that 81% of COVID-19 cases sequenced since April 2021 […]

UN 5th High Level Meeting on HIV/AIDS: Civil society says “Yes — AND” to the 2021 political declaration

By on .

The following is a guest post by Maureen Luba Milambe, African Regional Advocacy Advisor, AVAC On Tuesday (June 8), the UN General Assembly voted overwhelmingly to approve the 2021 Political Declaration on HIV and AIDS introduced as part of the now fifth High Level Meeting on HIV/AIDS. Previous Declarations were accepted by unanimous consent, following […]

HHS cites increasing rate of variants P.1 and B.351 in recommending use of Regeneron (but no longer Lilly) monoclonal antibody combination in eight states

By on .

By Daniel R. Lucey MD, MPH, FIDSA On Wednesday (May 26) the Department of Health and Human Services made the clinically-relevant important update below.  (I anticipate more than these eight states to be included in the weeks and months ahead as the variants P.1. and B.1. 351 continue to spread in the United States). ​“Important […]